PerkinElmer Inc at Cowen Health Care Conference Transcript
We have Max Krakowiak, CFO, PerkinElmer. Thank you to both of you for being here.
Just as a quick reminder, we made an out-of-consensus upgrade call on Perkin in early January. There have been 2 additional upgrade sense. Our view is that the company's recent acquisitions, particularly BioLegend and its forthcoming divestitures make the go-forward Perkin much different from the Legacy Perkin that many investors are familiar with. So with that said, our questions will be focused on the topics that we uncovered during our process of upgrading the stock.
So before we jump into some questions that are specific to the continuing operations, I just want to hit a few big picture questions.
Questions & Answers
Just latest expectations for when the planned business divestiture will close. Are there any risk factors that we should be aware of in terms of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
